Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.

Cancer control : journal of the Moffitt Cancer Center - 1 Jan 2000

Lyu Qiong, Lin Anqi, Cao Manming, Xu Abai, Luo Peng, Zhang Jian

Abstract excerpt

In recent years, immune checkpoint inhibitors (ICIs) targeting CTLA-4 or PD1/PDL1 have achieved remarkable success in the treatment of bladder cancer (BLCA), but only a few patients have shown durable clinical benefits. The prognostic role of a mutant form of the tumor suppressor gene TP53 (TP53-MT) in predicting the efficacy of ICIs is highly controversial; therefore, in this study, we obtained data for 210...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemokine CXCL10

Share to Datasets as Topic

Share to Immune Checkpoint Inhibitors

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33356494
DOI: 10.1177/1073274820976665
PMCID: PMC8480364

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.PMID 33356494Read ↗

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics studySemantic proximity Read ↗

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy.Semantic proximity Read ↗

A TP53-based immune prognostic model for muscle-invasive bladder cancer.Semantic proximity Read ↗

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune MicroenvironmentSemantic proximity Read ↗

Identification of tumor antigens and immune subtypes of bladder cancer for mRNA vaccine developmentSemantic proximity Read ↗

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read ↗

An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohortsSemantic proximity Read ↗

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.Semantic proximity Read ↗

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.Semantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.